Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inlexisertib in Combination With Anticancer Therapies in Advanced Malignancies
NCT05957367Phase 2Active, not recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of inlexisertib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Incidence of Adverse Events at 24 months, Recommended Phase 2 Doses at 18 months and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
inlexisertib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05957367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957367.